Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REVOL858R Phase 3 trial: erlotinib + ramucirumab versus osimertinib in untreated EGFR L858R-mutant NSCLC
jRCTs051200142Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2021
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of osimertinib, erlotinib and ramucirumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Time to failure of strategy (TFS). Started Mar 2021; status: active, not recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCTs051200142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051200142.